Jason Wu
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Emerging Leaders
not ranked
Current Leaders
#879 pts
All-Time Leaders
#12,6128 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2020. 23 trials as lead/chair. How it works →
Trials led — by scientific impact
A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
3
impact
A Multicenter, Randomized, Open-label Phase II Study of ZG005 Combined With Bevacizumab Versus Sintilimab Combined With Bevacizumab for First-line Treatment of Advanced Hepatocellular Carcinoma
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
3
impact
A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
3
impact
A Phase I/II Study to Evaluate Safety and Pharmacokinetics and Initial Efficacy of ZG005 in Combination With Paclitaxel Plus Cisplatin/Carboplatin ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
2
impact
A Single-dose, Randomized, Open-label, Four-period, Replicate Crossover, Comparative Pharmacokinetic Study of Two Formulations of Gecacitinib Hydrochloride Tablets in Healthy Adult Participants Under Fasting Conditions.
Phase 1ActiveSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase III, Multicenter, Randomized, Open-Label, Controlled Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Phase 3Not Yet RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase Ib Study Evaluating the Safety and Efficacy of ZG006 in Combination With PD-1/PD-L1 Immune Checkpoint Inhibitors as First-Line Standard Therapy in Participants With Extensive Stage Small-Cell Lung Cancer
Phase 1RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZGGS18 in Combination With ZG005 in Patients With Advanced Solid Tumors, Including Cervical Cancer, Hepatocellular Carcinoma, Neuroendocrine Tumors, and Lung Cancer
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer
Phase 2Not Yet RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Multicenter, Open-label, Dose-finding and Dose-expansion Phase I/II Study of ZG005 in Combination With Gecacitinib in Participants With Advanced Cervical Cancer
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Platinum-Based Chemotherapy as First-Line Treatment in Participants With Advanced Biliary Tract Carcinoma
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase II Study to Evaluate Efficacy, Safety, and Pharmacokinetics of ZG005 in Patients With Advanced Solid Tumors
Phase 2ActiveSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Multicenter, Open-label, Dose-Escalation and Dose-Expansion Phase I/II Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung Cancer
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Study to Evaluate the Efficacy and Safety of ZG005 in Combination With Gecacitinib and Chemotherapy for Participants With Advanced Solid Tumors
Phase 2Not Yet RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Phase 3RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase Ib/II Study of the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Combination With ZG005 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma(NEC)
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Study of ZG005 Combined With Donafenib Tosilate Tablets in Patients With Advanced Solid Tumor
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase I/II Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase III Extended Clinical Trial of Long-term Safety and Efficacy of Jaktinib Hydrochloride Tablets in the Treatment of Moderate and Severe Atopic Dermatitis
Phase 3UnknownSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Single-dose, Randomized, Open-label, Repeated Cross-over Pharmacokinetic Comparison Study of Two Formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers Under Fasted Conditions
Phase 1CompletedSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase 1 Dose Escalation and Expansion, Tolerability, Safety, Pharmacokinetics / Pharmacodynamics and Preliminary Efficacy Study of ZG0895.HCl in Patients With Advanced Solid Tumors
Phase 1RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase I/II Dose Escalation Study to Evaluating the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG2001 Tosilate Tablets in Participants With KRAS Mutated Advanced Solid Tumours
Phase 2UnknownSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase 1/2 Dose Escalation, Tolerability, Safety and Pharmacokinetics Study of ZG005 in Patients With Advanced Solid Tumors
Phase 2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Phase I/II Dose Escalation and Expansion Study to Evaluating the Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG19018 in Patients With KRAS G12C Mutant Advanced Solid Tumors.
Phase 2UnknownSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of Jaktinib in Healthy Volunteers
Phase 1CompletedSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Jaktinib in Adult Patients With Severe Alopecia Areata
Phase 3CompletedSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact
A Multicenter, Randomized, Double-Blind,Placebo-controlled,Phase 2 Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis
Phase 2CompletedSuzhou Zelgen Biopharmaceuticals Co.,LtdStudy Chair
0
impact